513 assets in Ovarian Cancer

Therapeutic assets addressing Ovarian Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Entrectinib Ovarian Cancer	OHSU Knight Cancer Institute	P2	CCC (50)
Fianlimab Ovarian Cancer	Regeneron Pharmaceuticals	P2	CCC (50)
Gleolan Ovarian Cancer	NX Development Corp	P3	CCC (50)
Gotistobart Ovarian Cancer	OncoC4, Inc.	P2	CCC (50)
Imiquimod Ovarian Cancer	Toray Industries, Inc	P2	CCC (50)
imp4927 Ovarian Cancer	Impact Therapeutics, Inc.	P3	CCC (50)
Ipatasertib Ovarian Cancer	National Cancer Institute (NCI)	P2	CCC (50)
Ivuxolimab Ovarian Cancer	Pfizer	P3	CCC (50)
Jskn003 Ovarian Cancer	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	P3	CCC (50)
Lorlatanib Ovarian Cancer	Pfizer	P3	CCC (50)
Metformin Ovarian Cancer	Dana-Farber Cancer Institute	P2	CCC (50)
Ny-Eso-1 Peptide Vaccine Ovarian Cancer	Georgetown University	P2	CCC (50)
Peg-Pei-Cholesterol Lipopolymer Ovarian Cancer	Imunon	P3	CCC (50)
Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin Dfp-13318 Ovarian Cancer	Mayo Clinic	P2	CCC (50)
Radspherin Ovarian Cancer	Oncoinvent Solutions AS	P2	CCC (50)
Rilvegostomig Ovarian Cancer	AstraZeneca	P2	CCC (50)
Sarilumab Ovarian Cancer	Regeneron Pharmaceuticals	P2	CCC (50)
Selinexor Ovarian Cancer	Loyola University	P2	CCC (50)
Toripalimab Ovarian Cancer	Georgetown University	P2	CCC (50)
Ubamatamab Ovarian Cancer	ARCAGY/ GINECO GROUP	P2	CCC (50)
Vodudeutentan Sodium Ovarian Cancer	Canadian Cancer Trials Group	P2	CCC (50)
[18f]f-resca-rt4 Ovarian Cancer	RenJi Hospital	P2/3	CCC (48)
[18F]F-RESCA-T4 Ovarian Cancer	RenJi Hospital	P2/3	CCC (48)
[68ga]ga-nota-rt4 Ovarian Cancer	RenJi Hospital	P2/3	CCC (48)
[68ga]ga-nota-t4 Ovarian Cancer	RenJi Hospital	P2/3	CCC (48)
al2846 Ovarian Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P2	CCC (48)
Autologous Natural Killer Cell-Like Ctls Ovarian Cancer	Roswell Park Cancer Institute	P1/2	CCC (48)
Immunoglobulin G1 [101-Glycine,234-Phenylalanine,235-Glutamic Acid,265-Alanine,405-Leucine,De-C-Terminal-Lysine], Anti-(Human Cd3 Antigen) (Human-Mus Musculus Monoclonal Igg1-Hucacao-H101G-Feal ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Igg1-Hucacao-H101G-Feal ?-Chain, (234?226?),(237?229?)-Bis(Disulfide) With Immunoglobulin G1 [234-Phenylalanine,235-Glutamic Acid,265-Alanine,409-Arginine] Anti-(Human B7 Homolog 4 Protein) (Human Monoclonal Igg1-7724-084-N52S-Fear ?1-Chain) Disulfide With Human Monoclonal Igg1-7724-084-N52S-Fear ?-Chain Ovarian Cancer	Genmab	P1/2	CCC (48)
Immunoglobulin G1 [300-Alanine], Anti-(Human Cd73 Antigen) (Human-Mus Musculus Monoclonal Tj004309 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Tj004309 ?-Chain, Dimer Ovarian Cancer	I-Mab Biopharma US Limited	P2	CCC (48)
Loperamide Ovarian Cancer	M.D. Anderson Cancer Center	P1/2	CCC (48)
Nilotinib Ovarian Cancer	National Cancer Institute (NCI)	P2	CCC (48)
Nuv-1511 Ovarian Cancer	Nuvation Bio Inc.	P1/2	CCC (48)
Pyruvate Ovarian Cancer	M.D. Anderson Cancer Center	P2	CCC (48)
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone Ovarian Cancer	Corcept Therapeutics	P2	CCC (48)
Regorafenib Ovarian Cancer	Sarah K. Lynam MD	P2	CCC (48)
Risovalisib Ovarian Cancer	Haihe Biopharma Co., Ltd.	P2	CCC (48)
Sk-Nk Cell Ovarian Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CCC (48)
Tivozanib Ovarian Cancer	University of Florida	P2	CCC (48)
Tocilizumab Ovarian Cancer	Regeneron Pharmaceuticals	P1/2	CCC (48)
Amxt1501 Ovarian Cancer	Aminex Therapeutics, Inc.	P1/2	CC (47)
Celecoxib Ovarian Cancer	Kalinski, Pawel, MD, PhD	P2	CC (47)
Devimistat Ovarian Cancer	Northwestern University	P2	CC (47)
Eflornithine Ovarian Cancer	Aminex Therapeutics, Inc.	P1/2	CC (47)
Gedatolisib Ovarian Cancer	Dana-Farber Cancer Institute	P2	CC (47)
gi-102 Ovarian Cancer	GI Innovation, Inc.	P1/2	CC (47)
Hbi 0201-Eso Tcrt Ovarian Cancer	Hadassah Medical Organization	P1/2	CC (47)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cdh6(Cadherin 6, K-Cadherin (Foetal Kidney), Cadherin 6 Type 2)], Humanized Monoclonal Antibody Conjugated To Deruxtecan, Comprising A Linker And A Camptothecin Derivative Ovarian Cancer	Merck Sharp & Dohme LLC	P1/2	CC (47)
rp12146 Ovarian Cancer	Rhizen Pharmaceuticals SA	P1	CC (47)
sc0191 Ovarian Cancer	Biocity Biopharmaceutics Co., Ltd.	P1/2	CC (47)
aur109 Ovarian Cancer	Aurigene Discovery Technologies Limited	P2	CC (46)

Showing 151 to 200 of 513 assets

PreviousPage 4 of 11Next